SLC5A9: A Drug Target and Biomarker for Sodium and Glucosehomeostasis

Target Name: SLC5A9

NCBI ID: G200010

SLC5A9: A Drug Target and Biomarker for Sodium and Glucosehomeostasis

Sodium and glucose are essential nutrients for the human body, but they have different effects on the body. Sodium is an essential electrolyte that helps regulate the balance of fluids in the body, while glucose is the primary source of energy for the body's cells. Sodium and glucose homeostasis are critical for maintaining the health and proper functioning of the body.

SLC5A9 is a protein that is expressed in many different tissues throughout the body. It is a sodium/glucose cotransporter 4 (isoform 2), which means it is responsible for transmitting sodium and glucose across cell membranes. SLC5A9 is a key regulator of sodium and glucose homeostasis, and it has been identified as a potential drug target and biomarker for several diseases.

SLC5A9 is expressed in many different tissues throughout the body, including the brain, pancreas, and heart. It is also expressed in the placenta, which plays a critical role in providing nutrients to the developing fetus. SLC5A9 is involved in regulating the balance of sodium and glucose in these tissues, and it is thought to be involved in several different diseases.

One of the potential benefits of SLC5A9 as a drug target is its ability to modulate sodium and glucose homeostasis in a variety of ways. SLC5A9 has been shown to regulate the levels of sodium and glucose in the brain, which is thought to play a role in several neurological disorders, including Alzheimer's disease and Parkinson's disease. SLC5A9 has also been shown to regulate the levels of glucose in the pancreas, which is thought to play a role in the development of type 2 diabetes.

In addition to its potential role as a drug target, SLC5A9 has also been identified as a potential biomarker for several diseases. For example, SLC5A9 has been shown to be decreased in individuals with type 2 diabetes, which is thought to be due to disruptions in sodium and glucose homeostasis. In addition, SLC5A9 has been shown to be decreased in individuals with Alzheimer's disease, which is thought to be due to disruptions in the levels of sodium and glucose in the brain.

Another potential benefit of SLC5A9 as a drug target is its ability to modulate sodium and glucose homeostasis in a variety of ways. SLC5A9 has been shown to regulate the levels of sodium and glucose in the brain, which is thought to play a role in several neurological disorders, including Alzheimer's disease and Parkinson's disease. SLC5A9 has also been shown to regulate the levels of glucose in the pancreas, which is thought to play a role in the development of type 2 diabetes.

In addition to its potential role as a drug target and biomarker, SLC5A9 is also thought to be involved in several other processes in the body. For example, SLC5A9 is involved in regulating the levels of water in the body, which is critical for maintaining the proper functioning of many different tissues and organs. SLC5A9 is also involved in regulating the levels of electrolytes in the body, which is important for maintaining the proper functioning of the body's cells and tissues.

Overall, SLC5A9 is a protein that is expressed in many different tissues throughout the body and is involved in regulating sodium and glucose homeostasis. Its potential as a drug target and biomarker for several diseases makes it an attractive target for research into the underlying mechanisms of these diseases. Further studies are needed to fully understand the role of SLC5A9 in

Protein Name: Solute Carrier Family 5 Member 9

Functions: Electrogenic Na(+)-coupled sugar symporter that may play a primary role in D-mannose and possibly D-fructose and D-glucose transport at the plasma membrane. Transporter activity is driven by a transmembrane Na(+) electrochemical gradient set by the Na(+)/K(+) pump. Exclusively recognizes sugar substrates having a pyranose ring with an axial hydroxyl group on carbon 2

More Common Targets